Vaginally administered PEGylated LIF Antagonist blocked embryo implantation and eliminated non-target effects on bone in mice

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Menkhorst, Ellen ^a   Zhang, Jian Guo ^b   Sims, Natalie A ^c   Morgan, Phillip O ^b   Soo, Priscilla ^b   Poulton, Ingrid J ^c   Metcalf, Donald ^b   Alexandrou, Estella ^d,e   Gresle, Melissa ^d   Salamonsen, Lois A ^a   Butzkueven, Helmut ^d,e   Nicola, Nicos A ^b   Dimitriadis, Evdokia ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; PEGYLATED LEUKEMIA INHIBITORY FACTOR ANTAGONIST; UNCLASSIFIED DRUG; LEUKEMIA INHIBITORY FACTOR; MACROGOL DERIVATIVE; PEGYLATED MH35 BD Q29A+G124R PROTEIN; PEGYLATED MH35-BD-Q29A+G124R PROTEIN; RADIOACTIVE IODINE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE REMODELING; CENTRAL NERVOUS SYSTEM; CONTRACEPTION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; FEMALE; FEMALE FERTILITY; MALE; MOUSE; MULTIPLE SCLEROSIS; NIDATION; NONHUMAN; TISSUE DISTRIBUTION; ANIMAL; BONE; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; EPITHELIUM; FERTILITY; HALF LIFE TIME; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT; REPRODUCTION; UTERUS;

ANIMALIA; MUS;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; BONE AND BONES; BONE REMODELING; CENTRAL NERVOUS SYSTEM; EMBRYO IMPLANTATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPITHELIUM; FEMALE; FERTILITY; HALF-LIFE; INJECTIONS, INTRAPERITONEAL; IODINE RADIOISOTOPES; LEUKEMIA INHIBITORY FACTOR; MALE; MICE; MICE, INBRED C57BL; POLYETHYLENE GLYCOLS; PROTEIN TRANSPORT; REPRODUCTION; UTERUS;

EID: 79956203803     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019665     Document Type: Article

References (50)

1. Kopf GS, (2007) Contraceptive development: targets, approaches, challenges. Soc Reprod Fertil Suppl 63: 21-31.
2. Global Health Council Available: http://www.globalhealth.org/womens_health/ Accessed 2007 June 11.
3. Prata N, (2009) Making family planning accessible in resource-poor settings. Philosophical transactions of the Royal Society B 364: 3093-3099.
4. Editorial, (2009) Sexual and reproductive health and climate change. The Lancet 374: 949.
5. Jewkes R, (2010) Gender inequities must be addressed in HIV prevention. Science 329: 145-147.
6. All Party Parliamentary Group on Population Development and Reproductive Health Return of the Population Growth Factor: Its Impact on the Millennium Development Goals Available: http://www.populationconnection.org/site/DocServer/Return_of_the_Population_Growth_Factorpdf?docID=224 Accessed 2011 April 15.
7. Paiva P, Menkhorst EM, Salamonsen LA, Dimitriadis E, (2009) Leukemia inhibitory factor and interleukin-11: Critical regulators in the establishment of pregnancy. Cytokine & Growth Factor Reviews 20: 319-328.
8. Stewart CL, Kaspar P, Brunet LJ, Bhatt H, Gadi I, et al. (1992) Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature 359: 76-79.
9. Kojima K, Kanzaki H, Iwai M, Hatayama H, Fujimoto M, et al. (1994) Expression of leukemia inhibitory factor in human endometrium and placenta. Biol Reprod 50: 882-887.
10. Charnock-Jones DS, Sharkey AM, Fenwick P, Smith SK, (1994) Leukaemia inhibitory factor mRNA concentration peaks in human endometrium at the time of implantation and the blastocyst contains mRNA for the receptor at this time. Journal of Reproduction and Fertility 101: 421-426.
11. Vogiagis D, Marsh MM, Fry RC, Salamonsen LA, (1996) Leukaemia inhibitory factor in human endometrium throughout the menstrual cycle. Journal of Endocrinology 148: 95-102.
12. Tsai HD, Chang CC, Hsieh YY, Lo HY, (2000) Leukemia inhibitory factor expression in different endometrial locations between fertile and infertile women throughout different menstrual phases. Journal of Assisted Reproduction and Genetics 17: 415-418.
13. Dimitriadis E, Sharkey AM, Tan YL, Salamonsen LA, Sherwin JRA, (2007) Immunolocalisation of phosphorylated STAT3, interleukin 11 and leukaemia inhibitory factor in endometrium of women with unexplained infertility during the implantation window. Reprod Biol Endocrin 5: 44.
14. Mikolajczyk M, Wirstlein P, Skrzypczak J, (2007) The impact of Leukemia Inhibitory Factor in uterine flushing on the reproductive potential of infertile women- a prospective study. Am J Reprod Immunol 58: 65-74.
15. Dimitriadis E, Stoikos C, Stafford-Bell M, Clark I, Paiva P, et al. (2006) Interleukin-11, IL-11 receptor[alpha] and leukemia inhibitory factor are dysregulated in endometrium of infertile women with endometriosis during the implantation window. Journal of Reproductive Immunology 69: 53-64.
16. Marwood M, Visser K, Salamonsen LA, Dimitriadis E, (2009) Interleukin-11 and Leukemia Inhibitory Factor Regulate the Adhesion of Endometrial Epithelial Cells: Implications in Fertility Regulation. Endocrinology 150: 2915-2923.
17. Shimomura Y, Ando H, Furugori K, Kajiyama H, Suzuki M, et al. (2006) Possible involvement of crosstalk cell-adhesion mechanism by endometrial CD26/dipeptidyl peptidase IV and embryonal fibronectin in human blastocyst implantation. Mol Hum Reprod 12: 491-495.
18. Kurosawa K, Isemura M, Yamaguchi Y, Yosizawa Z, Furuyama T, et al. (1985) Changes in distribution of connective tissue components of human placentae with maturation. Tohoku J Exp Med 147: 261-265.
19. White CA, Zhang J-G, Salamonsen LA, Dimitriadis E, et al. (2007) Blocking LIF action in the uterus by using a PEGylated antagonist prevents implantation: a nonhormonal contraceptive strategy. PNAS 104: 19357-19362.
20. Fairlie WD, Uboldi AD, McCoubrie JE, Wang CC, Lee EF, et al. (2004) Affinity Maturation of Leukemia Inhibitory Factor and Conversion to Potent Antagonists of Signaling. Journal of Biological Chemistry 279: 2125-2134.
21. Bozec A, Bakiri L, Hoebertz A, Eferl R, Schilling AF, et al. (2008) Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature 454: 221-226.
22. Ware CB, Horowitz MC, Renshaw BR, Gearing DP, et al. (1995) Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development 121: 1283-1299.
23. Walker EC, McGregor NE, Poulton IJ, Pompolo S, Allan EH, et al. (2008) Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. Journal of Bone and Mineral Research 23: 2025-2032.
24. De Ziegler D, Bulletti C, De Monstier B, Jaaskelainen AS, (1997) The first uterine pass effect. Ann NY Acad Sci 828: 291-299.
25. Cicinelli E, de Ziegler D, (1999) New Hypotheses. Transvaginal progesterone: evidence for a new functional 'portal system' flowing from the vagina to the uterus. Human Reproduction Update 5: 365-372.
26. Ficicioglu CMJ, (2004) High local endometrial effect of vaginal progesterone gel. Gynecological endocrinology 18: 240-243.
27. Devoto L, Fuentes A, Palomino A, Espinoza A, Kohen P, et al. (2005) Pharmacokinetics and endometrial tissue levels of levonorgestrel after administration of a single 1.5-mg dose by the oral and vaginal route. Fertility and Sterility 84: 46-51.
28. Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, et al. (2000) Direct transport of progesterone from vagina to uterus. Obstetrics & Gynecology 95: 403-406.
29. Cicinelli E, Rubini G, De Ziegler D, Barba B, Pinto V, et al. (2001) Absorption and preferential vagina-to-uterus distribution after vaginal administration of 99mTc-pertechnetate in postmenopausal women. Fertility and Sterility 76: 1108-1112.
30. Cicinelli E, de Ziegler D, Morgese S, Bulletti C, Luisi D, et al. (2004) "First uterine pass effect" is observed when estradiol is placed in the upper but not lower third of the vagina. Fertility and Sterility 81: 1414-1416.
31. Brache V, Croxatto H, Sitruk-Ware R, Maguire R, Montero JC, et al. (2007) Effect of a single vaginal administration of levonorgestrel in Carraguard(R) gel on the ovulatory process: a potential candidate for "dual protection" emergency contraception. Contraception 76: 111-116.
32. Benagiano G, Gabelnick H, Farris M, (2008) Contraceptive devices: intravaginal and intrauterine delivery systems. Expert Rev Med Devices 5: 639-654.
33. Karim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of Tenofovir Gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
34. Menkhorst E, Salamonsen LA, Robb L, Dimitriadis E, (2009) IL11 antagonist inhibits uterine stromal differentiation, causing pregnancy failure in mice. Biology of Reproduction 80: 920-927.
35. Sims NA, Brennan K, Spaliviero J, Handlesman DJ, Seibel MJ, (2006) Perinatal testosterone surge is required for normal adult bone size but not for normal bone remodeling. American Journal of Physiology, Endocrinology and Metabolism 290: E456-462.
36. Butzkueven H, Zhang J-G, Soilu-Hanninen M, Hochrein H, Chionh F, et al. (2002) LIF receptor signalling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nature Medicine 8: 613-619.
37. Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, et al. (2002) CTNF is a major protective factor in demyelinating CNS disease: a neuroprotective cytokine as modulator in neuroinflammation. Nature Medicine 8: 620-624.
38. Slavin A, Ewing C, Liu J, Ichikawa M, Slavin J, et al. (1998) Induction of a multpile sclerosis-like disease in mice with an immunodomiant epitope of myelin oligodendrocyte glycoprotein. Autoimmunity 28: 109-120.
39. Shaw G, Yang C, Ellis R, Anderson K, Mickle J, et al. (2005) Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. Biochem Biophys Res Commun 336: 1268-1277.
40. Hilton DJ, Nicola NA, Waring PM, Metcalf D, (1991) Clearance and fate of Leukemia-Inhibitory Factor (LIF) after injection into mice. Journal of Cellular Physiology 148: 430-439.
41. Hussain A, Ahsan F, (2005) The vagina as a route for systemic drug delivery. Journal of Controlled Release 103: 301-313.
42. Cornish J, Callon K, King A, Edgar S, Reid IR, (1993) The effect of leukemia inhibitor factor on bone in vivo. Endocrinology 132: 1359-1366.
43. Walker EC, McGregor NE, Poulton IJ, Solano M, Pompolo S, et al. (2010) Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. Journal of Clinical Investigation 120: 582-592.
44. Kovacs CM, Kronenberg HM, (1997) Maternal-fetal calcium and bone metabolism during pregnancy, puerperium and lactation. Endocrine Reviews 18: 832-872.
45. Martin TJ, Seeman E, (2007) New mechanisms and targets in the treatment of bone fragility. Clinical Science 112: 77-91.
46. Herrmann M, Seibel MJ, (2010) The effects of hormonal contraceptives on bone turnover markers and bone health. Clinical Endocrinology 72: 571-583.
47. Bahamondes L, Espejo-Arce X, Hidalgo MM, Hidalgo-Regina C, Teatin-Juliato C, et al. (2006) A cross-sectional study of the forearm bone density of long-term users of levonorgestrel-releasing intrauterine system. Human Reproduction 21: 1316-1319.
48. Butzkueven H, Emery B, Cipriani T, Marriott M, Kilpatrick TJ, (2006) Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss. Glia 53: 696-703.
49. Aitken RJ, Baker MA, Doncel GF, Matzuk MM, Mauck CK, et al. (2008) As the world grows: contraception in the 21st century. The Journal of Clinical Investigation 118: 1330-1343.
50. Kilmarx PH, (2009) Global epidemiology of HIV. Current opinion in HIV & AIDS 4: 240-246.